You are here: Industry Insights > AstraZeneca

News List

Avella selected by AstraZeneca to distribute CALQUENCE (acalabrutinib) biospectrumasia
November 02, 2017
The specialty pharmacy will provide access to this FDA-approved, second-generation treatment for mantle cell lymphoma.
AstraZeneca licenses genetic disease drug to Mereo Biopharma for $5 million, becomes shareholder pharmafile
October 31, 2017
AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin deficiency, to Mereo Biopharma for an upfront cash payment of $3 million plus 490,728 shares, making a total of $5 million
AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review fiercepharma
October 19, 2017
The agency Wednesday accepted the British drugmaker’s approval application and granted the medication its “priority review” tag.
AstraZeneca Pharma gets DCG(I) nod to market diabetes drug expressbpd
October 19, 2017
AstraZeneca Pharma has received marketing authorisation from the Drug Controller General India DCG(I) for Xigduo XR tablets used in treatment of adults with type II diabetes in India.
AstraZeneca’s Faslodex receives CHMP opinion for advanced breast cancer treatment pharmaceufical-technology
October 18, 2017
Advanced / metastatic breast cancer refers to Stage III and IV breast cancer
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours pharmafile
October 18, 2017
AstraZeneca and its partner and Chinese medicine (also known as Chi-Med) have announced positive data on savolitinib combined with AstraZeneca's Tagrisso or Iressa
AstraZeneca admits cancer data for acquired drug was fabricated pharmafile
October 17, 2017
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
AstraZeneca announces that Tagrisso granted breakthrough therapy designation (BTD) by US FDA pharmaasia
October 17, 2017
Tagrisso is a first-line treatment for EGFR mutation-positive non-small cell lung cancer. This is the sixth BTD for an AstraZeneca New Oncology medicine.
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients w worldpharmanews
October 12, 2017
AstraZeneca announced that the US FDA)has granted Breakthrough Therapy Designation for Tagrisso for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer
AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC pharmafile
October 10, 2017
AstraZeneca has announced that its immunotherapy Tagrisso has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page